Caxton Corporation’s Spyre Therapeutics SYRE Stock Holding History

Caxton Corporation’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,919	Closed	-$292K	–	12
2025 Q4	$292K	Buy	+8,919	New	+$233K	6.83%	3

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Caxton Corporation's SYRE Position: Q1 2026 in Review

Caxton Corporation sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 8,919 shares — an estimated $292K sold.

Caxton Corporation first reported a position in SYRE in Q4 2025 and held it in 1 quarter. The position peaked at $292K in Q4 2025. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

Caxton Corporation reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
Caxton Corporation sold 8,919 Spyre Therapeutics shares in Q1 2026, an estimated $292K.
Caxton Corporation first reported a position in Spyre Therapeutics in Q4 2025 and held it in 1 quarter.
Caxton Corporation's Spyre Therapeutics position peaked at $292K in Q4 2025.
198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.